2022 Interview Spotlight Series: Part II

-

This week on Simply Blood we continue our 2022 Interview Spotlight Series. In Part II we are featuring the ISEH 2022 Janet Rowley Awardee: David Kent, PhD. Here, Dr. Kent answers questions about his scientific passions, career path, mentorship and more. Interested in hearing more about Dr. Kent’s fascinating work? Don’t miss his session at the ISEH 51st Annual Scientific Meeting this September!







Dr David Kent
York Biomedical Research Institute
Department of Biology
University of York, York, UK








Interviewed by Francois Mercier, ISEH New Investigators Committee & Beth Psaila, ISEH Junior PI Committee. 

Comments

Post a Comment

Popular posts from this blog

2020 Interview Spotlight Series: Part II

-
Image
This week on  Simply Blood  we are continuing our 2020 Interview Spotlight Series. In Part II we are featuring the ISEH 2020 New Investigator's Invitee:  Elisa Laurenti, MBS; PhD . Dr. Laurenti answers questions about her work, trends in hematology, mentorship, and more. Have additional questions for Dr. Laurenti? Don't miss her session at this year's  Virtual Scientific Meeting . 1. How would you describe your science? Ultimately, I want to contribute to the understanding of how such a complex cellular system as blood production is set up and maintained. Currently my laboratory is particularly interested in how haematopoiesis changes throughout a human life, starting from the embryo all the way to the old age. From my PhD, I have been fascinated by cellular quiescence, and why its molecular regulation is such an important feature to maintain healthy blood production. Now my laboratory looks at how understanding quiescence networks can contribute to gene therapy and ex vivo
Read more

COVID 19 Series: Happy Hour Wrap-Up

-
Image
On April 10th, ISEH hosed a webinar – actually more of a ‘Happy Hour’ to discuss the impact of COVID-19 on academic laboratories across the world.  Led by an impromptu panel of investigators (Camilla Forsberg, Trista North, Ross Levine, Len Zon, Kristina Kirshner, Momoko Yoshimoto-Kobayashi, Hanna Mikkola, Jennifer Trowbridge and Grant Rowe), we discussed the impact the global pandemic on our laboratory operations, our careers and those of trainees, and transitioning to work from home.  Katie Strang and Dovile Svirupskaite mediated the event and answered questions on the side in the parallel chat conversation. We are looking forward to holding another virtual meeting in the coming weeks to touch on these issues and new challenges faced by investigators all over the world. Here, we will present some highlights: On laboratory operations Most panelists faced a total shutdown of laboratory research, with access to facilities limited to ‘essential personnel’ necessary to mainta
Read more

Exploring Experimental Hematology: June 2021 (Volume 98)

-
Image
DNA methylation therapy joins forces in IDH2 -mutant AML Isocitrate dehydrogenases 1 and 2 ( IDH1 /2) are frequently mutated in Acute Myeloid Leukemia (AML), with nearly 20% of patients carrying gain-of-function point mutations in these genes (Ley et al., 2013) . IDH2 is a metabolic enzyme that catalyzes the conversion of isocitrate to 2-oxoglutarate during the Krebs cycle. Patients carrying IDH2 gain-of-function mutations produce instead high levels of the oncometabolite 2-hydroxyglutarate (2-HG), which inhibits oxoglutarate-dependent enzymes such as the TET family of methylcytosine dioxygenases, responsible for active DNA demethylation (Xu et al., 2011) . As a consequence, IDH2 mutations in AML patients induce DNA hypermethylation and inhibit hematopoietic differentiation (Figueroa et al., 2010) . Azacytidine (AZA) and enasidenib (ENA) are commonly used AML therapies which induce DNA hypomethylation, albeit through different mechanisms. AZA is a nucleoside analog that inhibits
Read more